The cobas eplex BCID panels provide broad coverage of organisms that can lead to sepsis along with their resistance genes.
The cobas eplex blood culture identification panels (BCID) broad coverage means that about 95% of currently identified bloodstream infections can be detected early, compared to other panels that detect significantly fewer sepsis-causing bacteria and fungi.
Infectious diseases, such as bloodstream infections that can lead to sepsis, respiratory infections and diarrhea are among the top causes of death worldwide.1,2
These and other infectious diseases can be considered syndromes (a group of symptoms that may not point to a specific causative agent) and may be difficult to diagnose using conventional diagnostic testing methods that look for a single or small number of disease-causing pathogens.
It is estimated that 20-30% of patients receive ineffective initial antibiotic therapy and the mortality rate for these patients increases up to 7.6% for every hour effective antibiotics are delayed.3,4
The cobas eplex BCID panels aid you in the identification of bacterial and fungal organisms as well as antibiotic resistance genes in about 90 minutes of blood culture bottle positivity, allowing treatment decisions to occur days earlier than with conventional methods. Unique solutions, like the cobas eplex system, can help to improve antimicrobial stewardship and optimize patient care.
The cobas eplex BCID panels offer the broadest coverage5,6 of organisms and resistance markers that cause bloodstream infections (BSI) and can lead to sepsis, including anaerobes and multi-drug resistant organisms (MDRO), as well as common and emerging fungal pathogens (Table 1). The cobas eplex blood culture identification fungal pathogen panel (BCID-FP) was the first FDA-cleared multiplex molecular panel to include Candida auris, a multi-drug resistant fungal organism that is increasing in prevalence around the world.7
The cobas eplex BCID panels detect more of the organisms that cause bloodstream infections than other multiplex panels.
% organism inclusivity |
|||
| 5 US hospitals | Clinical study | Weighted average | |
| Number of samples (n) | 15,793 | 1,979 | 17,772 |
| cobas® eplex BCID panels | 94.1% | 93.6% | 94.0% |
| BioFire BCID | 84.3% | 86.6% | 84.5% |
| BioFire BCID v2 | 86.8% | 89.1% | 87% |
| Luminex Verigene BC¹ | 83.1% | 83.0% | 83.1% |
| Accelerate Pheno BC ID | 78.1% | 82.1% | 78.5% |
| Accelerate Pheno BC AST | 68.5% | 74.4% | 69.1% |
The cobas eplex BCID panels include 4 gram-positive and 6 gram-negative resistance genes that can be detected days earlier than conventional antimicrobial susceptibility tests (AST), enabling earlier escalation of therapy for resistant organisms or de-escalation of empirical antimicrobials in the case of common contaminants or when a narrower antibiotic is more appropriate. Rapid detection of antibiotic resistance genes when applied with local epidemiology of resistance, has been shown to have a high percent agreement with subsequent phenotypic susceptibility testing, allowing for recommendation of a targeted therapy earlier.8
As much as 15 to 30% of positive blood cultures may be due to contaminants which can result in continuation of unnecessary antibiotics.9 The cobas eplex BCID panels are designed to allow you to more rapidly differentiate a contaminant from a true infection, enabling rapid de-escalation and discharge of patients with a bloodstream infection 2-3 days earlier than conventional methods. Common contaminants included on the cobas eplex BCID-GP panel but not on most competitor’s panels include:
Candida albicans
Candida auris
Candida dubliniensis
Candida famata
Candida glabrata
Candida guilliermondii
Candida kefyr
Candida krusei
Candida lusitaniae
Candida parapsilosis
Candida tropicalis
Cryptococcus gattii
Cryptococcus neoformans
Fusarium
Rhodotorula
True sample-to-answer solution
The cobas eplex system integrates the entire process from order-to-report to better realize the patient and laboratory benefits of rapid, multiplex molecular diagnostics.
References
